Skip to content
mapperlab
← Dashboard
Stock

PRLD

PRELUDE THERAPEUTICS INC
Latest close $4.345 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
6
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 9, 2024Nov 14, 2024Nov 14, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$5.10$4.34-15%
Citadel Advisors re-entered$5.16$4.34-16%
Two Sigma Investments$5.16$4.34-16%
Millennium Management$1.03$4.34+321%
Point72 Asset Management$2.11$4.34+106%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
AQR Capital Management→ $2.11+118%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Prelude Therapeutics Inc. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
5
Filings · last 90d
9
Total on file
156
Recent SEC buffer
Most recent
May 4, 2026

30d / 90d windows measured from May 4, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 156 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · PRELUDE THERAPEUTICS INC

Annual figures sourced directly from PRELUDE THERAPEUTICS INC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$12.14M
FY2025+73% YoY
Net income
-$99.5M
FY2025+22% YoY
EPS (diluted)
$-1.29
FY2025+23% YoY
Free cash flow(?)
-$56.37M
FY2025+46% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Prelude Therapeutics Inc — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ2 2026open$4.48$4.34-3%
Point72 Asset ManagementQ1 2026open$2.11$4.34+106%
AQR Capital ManagementQ1 2025Q1 2026$0.97$2.11+118%
Millennium ManagementQ4 2024open$1.03$4.34+321%
Citadel AdvisorsQ3 2024Q4 2025$5.16$1.52-71%
Two Sigma InvestmentsQ3 2024open$5.16$4.34-16%
Renaissance TechnologiesQ3 2024open$5.10$4.34-15%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.